Compare EVCM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVCM | NRIX |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | EVCM | NRIX |
|---|---|---|
| Price | $10.96 | $16.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $11.50 | ★ $29.46 |
| AVG Volume (30 Days) | 133.1K | ★ 1.3M |
| Earning Date | 03-12-2026 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $718,038,000.00 | $83,980,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.60 | $20.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 22.13 | ★ 53.95 |
| 52 Week Low | $7.66 | $8.18 |
| 52 Week High | $14.41 | $22.50 |
| Indicator | EVCM | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 39.80 |
| Support Level | $10.40 | $16.15 |
| Resistance Level | $12.40 | $17.50 |
| Average True Range (ATR) | 0.65 | 1.10 |
| MACD | -0.20 | -0.32 |
| Stochastic Oscillator | 22.90 | 11.87 |
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.